Avient Corporation (NYSE:AVNT) - A Mid-Cap Stock Worth Considering Despite Undervaluation

OPKO Health's recent share price move to $1.34 has investors reassessing the company's valuation. The company's diagnostics and pharmaceutical businesses line up with its current valuation, with a fair value of $3.62. However, ongoing net losses and share dilution could undercut the optimistic valuation narrative. The P/S ratio suggests the market is already paying up for future progress, with a gap between OPKO's ratio and peers.